PCOS renamed PMOS in The Lancet (May 12, 2026) after 11-year, 22,000-respondent global consensus — reframes a 'reproductive' diagnosis as a multisystem endocrine-metabolic disorder affecting ~170 million women worldwide; AIIMS Delhi flags adoption in India

On May 12, 2026, a paper in The Lancet — co-launched at the European Congress of Endocrinology in Prague — formally renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). The change is the culmination of an 11-year multistep global consensus process led by 56 patient and professional organisations, including the Endocrine Society, drawing on more than 22,000 patient and clinician survey responses from 90+ countries. Indian institutions, prominently AIIMS Delhi, immediately highlighted the rename and its implications for India, where the condition is estimated to affect roughly one in five women of reproductive age — among the highest national prevalence in the world. The story matters for Current Affairs because it is a rare instance of a major disease being globally renamed, and because it foregrounds non-communicable disease policy in India.

Why the rename? The original term — Polycystic Ovary Syndrome — was medically misleading on two counts. First, the 'cysts' on the ovaries are arrested follicles (immature eggs that failed to mature and release) — *not* pathological cysts in the medical sense. Second, the name framed the condition narrowly as a reproductive disorder when, in fact, it is a multisystem condition affecting the endocrine (hormonal), metabolic (insulin and energy), reproductive, psychological and dermatological systems. The new name — *Polyendocrine Metabolic Ovarian Syndrome* — explicitly captures all four pathways: integrated insulin, androgen, neuroendocrine, and ovarian hormone dysregulation producing metabolic, reproductive, psychological, and dermatological sequelae.

The pathophysiology has three interlocking drivers. (1) Insulin Resistance — body cells under-respond to insulin, blood sugar rises, the pancreas pumps out more insulin (hyperinsulinemia), and high insulin signals the ovary's theca cells to produce excess androgens (masculine hormones). (2) Hormonal imbalance — elevated androgen plus elevated Luteinizing Hormone (LH) disrupt ovulation, producing irregular or absent menstrual cycles. (3) Low-grade chronic inflammation — research shows persistent low-grade systemic inflammation in affected women that itself stimulates polycystic ovaries to produce androgens. A strong genetic/hereditary component is documented, with particularly high familial clustering in the Indian population. Clinical diagnosis still uses the Rotterdam Criteria (2003) — meeting any two of: oligo-/anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. The authors have laid out a 3-year managed transition (2026–2029) to migrate health-system codes (ICD-11), research databases, clinical guidelines and patient education materials from PCOS to PMOS — a deliberate window to avoid confusion in patient care and insurance claims.